Epilepsy is an economic burden for people with epilepsy and for the community. Patients with epilepsy have to cope with the economic consequences, for example unemployment or underemployment. Epilepsy also has a major economic impact on society as a whole. As recent studies in various countries show, a considerable amount of health-care expenditure is spent on people with epilepsy.
Economic factors are playing an increasing role in decision-making processes today and determine the standard of epilepsy care. It has come to be recognized that the costs have a significant impact on the distribution of epilepsy services. The International League against Epilepsy (ILAE) has seen the importance of economic aspects for the development of epilepsy care. Therefore, two years ago, Ted Reynolds, President of the ILAE established a new body, the Commission on Economic Aspects of Epilepsy.
First, we have to realize that financial resources for the health care sector are limited This was a fact before politicians and economic experts began to talk about curbing the cost of health care; limited resources are not a historic exception but the normal situation. From a historic viewpoint periods of rapid growth are usually quite short. The idea that our health-care system is able to offer the maximum of health care to all its members might be a tempting illusion but it simply is not true. Even today, in a small and rich country like Switzerland, health-care services are unevenly spread through the country.
Secondly, political decisions about a budget or a project are often based on economic arguments. Costbenefit considerations guide decisions on the allocation of health-care services, Major'investments have to be based on cost-benefit studies. For example, in the case of major investment in epilepsy surgery, cost-benefit studies are particularly needed. Further to this, the introduction of new antiepileptic drugs (AED), prior to registration and recovery of costs from health budgets, have to show that their cost effectiveness is reasonable in comparison with those drugs, already available.
Measured against the massive influence of finance on the availability of epilepsy services, we have to realize that little is known about the real cost of epilepsy and the economic benefit of a particular type of treatment.
THE COST OF EPILEPSY
In discussing the cost of epilepsy today, a distinction must be drawn between the cost to the individual patient and the cost of epilepsy care to society at large. It is important to see that epilepsy is an economic burden for the individual patient. Many patients with epilepsy have to cope with unemployment or underemployment. This is generally felt to be more serious than the additional cost occasioned by epilepsy.
Epilepsy also has a major economic impact on the community as a whole. In the health economy, the issue of 'cost of illness' has been discussed for some time. The term 'cost of illness' means the total cost that arises for the community of a particular illness, such as the cost of diabetes, rheumatism or AIDS. Only recently has this kind of calculation been applied to the illness of epilepsy. Such studies about the'cost of epilepsy in the UK, USA, Australia, Sweden, Switzerland, and other countries were presented The studies carried out up to now do not show a uniform picture. Also they make use of different models for calculating costs. Some studies leave out the non-medical costs, whilst others take into account disability pensions. However, we recommend that neither disability pensions nor unemployment benefit be included, as these are considered to be transfer payments.
When discussing these different models, we came to the basic conclusion that only those costs that should be taken into account are, those incurred directly by epilepsy. The results would be unrepresentative if all costs for all people suffering from epilepsy were calculated. For many handicapped patients having seizures, the high cost of nursing is not only caused by epilepsy. In other words curing epilepsy would not mean that costs of caring for these handicapped patients would be removed.
Furthermore, the calculation of the cost is just one side of the cost-benefit equation. The cost of epilepsy care does not tell us much about its effectiveness. Therefore, economic arguments always have to be based on both cost and benefit.
THE COST-BENEFIT EVALUATIONS
A precondition of cost-benefit evaluations is that one must be able to quantify the benefit side in some way. A widely used standard is, for example, the reduction of the seizure frequency. For people suffering from epilepsy, this is generally an important factor in their quality of life. However, there can be no doubt that this is not the only criteria for the benefits. There are other indicators for measuring the benefit of a particular treatment. For this reason, the ILAE has established a special commission for the subject of 'Outcome Measurement'.
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From the economical viewpoint, the costs of new AED are a current theme. Charles Begley ef al ' (1994) in their study 'Cost of epilepsy in the USA', found that AED take up 38% of the total medical costs of epilepsy. Even if the proportion of drug costs in this study appears relatively high, it can be seen that the AED costs are significant.
The costs of AED have, therefore, been brought into the spotlight, because new drugs are several times more expensive than older, more familiar drugs. David Chadwick, chairman of the ILAE Commission on Anti-epileptic Drugs, stated that treatment with the new medicines can be more than 100 times more expensive than treatment with phenobarbital. This is, of course, due to the extraordinary low price of phenobarbital, which has been used as a basis for comparison. The higher costs, however, are impressive and enhance the need for economic evaluation.
Comparison between old and new drugs raises the question of additional costs and additional benefits. The comparison of cost with benefit has a major political impact on the reimbursement and distribution of new AED. The authorities who finance the medicines have an interest in testing the economical effectiveness of a new drug. This means that, alongside the medical effect, the economic efSectiveness of the new dmg must also be proved.
For providers of epilepsy services, economics must not be allowed to result in a situation in which economic goals become an end in themselves. On the contrary, economics must help to ensure the better attainment of the goals of epilepsy care. A better knowledge of the economic factors will improve the further development of epilepsy services, particularly the development and registration of new AED.
